Results for tag: "Denileukin Diftitox"

Denileukin diftitox (trade name Ontak) is a recombinant fusion protein used to treat cutaneous T-cell lymphoma (CTCL). It is a type of biologic therapy, which works by targeting and killing cancer cells. Denileukin diftitox is a combination of two proteins, interleukin-2 (IL-2) and diphtheria toxin. IL-2 binds to receptors on the surface of cancer cells, while diphtheria toxin is a toxin that kills the cells. Denileukin diftitox is administered intravenously and is used in combination with other treatments, such as chemotherapy and radiation therapy. Denileukin diftitox is approved by the U.S. Food and Drug Administration (FDA) for the treatment of CTCL. It is also used off-label to treat other types of lymphoma, such as peripheral T-cell lymphoma and Hodgkin's lymphoma. Companies in the Denileukin Diftitox market include Eisai Co., Ltd., Merck & Co., Inc., and Spectrum Pharmaceuticals, Inc. Show Less Read more